Prediction of relapse-free survival in stage III gastric cancer patients treated with postoperative adjuvant chemotherapy: Random survival forest analysis from the START-2 trial. This is an ASCO ...

The European Commission has granted marketing authorisation (MA) for Eli Lilly's ramucirumab (Cyramza) in stomach cancer, making it the first therapy approved for second-line advanced stomach and ...

FOLFIRI-ramucirumab (FOLFIRI-Ram) versus ramucirumab-paclitaxel (Ram-Pac) in the second line (2L) for patients with advanced upper gastrointestinal (UGI) cancer: A real-world propensity-score matched ...

The study, which evaluated the efficacy and safety of evorpacept in combination with trastuzumab, ramucirumab, and paclitaxel, demonstrated an overall response rate (ORR) of 41.3% in the intent-to ...